1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. mAChR

mAChR

mAChR

Muscarinic acetylcholine receptor

mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W743804
    Aclidinium-d5 bromide
    Antagonist
    Aclidinium-d5 (LAS 34273-d5; LAS-W 330-d5) bromide is deuterium-labeled Aclidinium Bromide (HY-14144).
    Aclidinium-d<sub>5</sub> bromide
  • HY-90010R
    Tolterodine (tartrate) (Standard)
    Antagonist
    Tolterodine (tartrate) (Standard) is the analytical standard of Tolterodine (tartrate). This product is intended for research and analytical applications. Tolterodine Tartrate (Kabi-2234; PNU-200583E) is a potent muscarinic receptor antagonist and shows selectivity for the urinary bladder over salivary glands in vivo.
    Tolterodine (tartrate) (Standard)
  • HY-129826
    J-104129
    Antagonist
    J-104129 is a selective and orally active muscarinic M3 receptor antagonist (Ki = 4.2 nM). J-104129 is effective in promoting bronchodilation.
    J-104129
  • HY-B0267AR
    Oxybutynin chloride (Standard)
    Antagonist
    Oxybutynin (chloride) (Standard) is the analytical standard of Oxybutynin (chloride). This product is intended for research and analytical applications. Oxybutynin chloride is an oral active and competitive mAChR antagonist with Kis of 14.3 and 5.55 nM for specific [3H]NMS binding in the mouse bladder and cerebral cortex, respectively. Oxybutynin chloride inhibits vascular Kv channels in a manner independent of anticholinergic effect, with an IC50 value of 11.51 μM. Oxybutynin chloride reduces muscle spasm in the bladder and urinary tract, can be used in study of overactive bladder syndrome (OAB). Oxybutynin (chloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Oxybutynin chloride (Standard)
  • HY-A0083C
    Methacholine iodide
    Agonist
    Methacholine iodide is a potent muscarinic-3 (M3) agonist. Methacholine iodide acts directly on acetylcholine receptors on smooth muscle causing bronchoconstriction and airway narrowing. Methacholine iodide shows a high sensitivity to identify bronchial hyperresponsiveness (BHR). Methacholine iodide can be used to measure airway hyperresponsiveness (AHR) as a diagnostic aid in the assessment of individuals with asthma-like symptoms and normal resting expiratory flow rates.
    Methacholine iodide
  • HY-120576
    ML169
    Modulator
    ML169 (VU0405652) is a potent, selective and brain penetrant positive allosteric modulator (PAM) of M1 mAChR, with an EC50 of 1.38 µM. ML169 is a MLPCN probe and can be used for Alzheimer’s disease.
    ML169
  • HY-148527
    LAS190792
    Antagonist
    LAS190792 (AZD8999) is a potent muscarinic antagonist and β2-adrenoceptor agonist with pIC50 8.9, 8.8, 8.8, 9.2, 8.2, 7.5, 9.1, 5.6 for M1, M2, M3, M4, M5, β1, β2, β3, respectively. LAS190792 can be used as a bronchodilator.
    LAS190792
  • HY-136634
    BTM-1042
    Inhibitor
    BTM-1042 is a newly synthesized compound with antispasmodic effects. It can inhibit the twitch reaction of the guinea pig ileum under electrical stimulation and is not affected by naloxone. It has similar effects to atropine and can block muscarinic receptors, but has less effect on other types of receptors. BTM-1042 also has an inhibitory effect on the ileal reaction caused by nicotine and 5-hydroxytryptamine. BTM-1042 showed a dose-dependent inhibitory effect on the spontaneous movement of the rabbit stomach. In general, BTM-1042 is a agent with a strong antispasmodic effect.
    BTM-1042
  • HY-A0030S
    Fesoterodine-d7 fumarate
    Fesoterodine-d7 (fumarate) is the deuterium labeled Fesoterodine fumarate[1]. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB)[2][3].
    Fesoterodine-d<sub>7</sub> fumarate
  • HY-B1487R
    Procyclidine (hydrochloride) (Standard)
    Antagonist
    Procyclidine (hydrochloride) (Standard) is the analytical standard of Procyclidine (hydrochloride). This product is intended for research and analytical applications. Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy.
    Procyclidine (hydrochloride) (Standard)
  • HY-13204R
    Biperiden (hydrochloride) (Standard)
    Inhibitor
    Biperiden (hydrochloride) (Standard) is the analytical standard of Biperiden (hydrochloride). This product is intended for research and analytical applications. Biperiden (KL 373) hydrochloride is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden hydrochloride has the potential for the research of Parkinson's disease and other related psychiatric disorders.
    Biperiden (hydrochloride) (Standard)
  • HY-149733
    M1/M2/M4 muscarinic agonist 3
    Agonist
    M1/M2/M4 muscarinic agonist 3 (compound 45) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 3.2 nM, 32 nM and 1.7 nM, respectively.
    M1/M2/M4 muscarinic agonist 3
  • HY-17360R
    Tiotropium (Bromide) (Standard)
    Antagonist
    Tiotropium (Bromide) (Standard) is the analytical standard of Tiotropium (Bromide). This product is intended for research and analytical applications. Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.
    Tiotropium (Bromide) (Standard)
  • HY-113616
    VU0364572
    Agonist
    VU0364572 is a selective allosteric agonist of the M1 muscarinic receptor with an EC50 of 0.11 μM. VU0364572 has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 is orally active and is CNS penetrant.
    VU0364572
  • HY-17360S1
    Tiotropium-d6 bromide
    Antagonist
    Tiotropium-d6 (bromide) is deuterium labeled Tiotropium (Bromide). Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.
    Tiotropium-d<sub>6</sub> bromide
  • HY-107652
    AF-DX 384
    Antagonist 98.0%
    AF-DX 384 is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively). AF-DX 384 reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine.
    AF-DX 384
  • HY-151801
    DIBA-Cy5
    DIBA-Cy5 is a fluorescent DIBA antagonist made up be DIBA-alkyne binding Cyanine5 fluorophores (Cy5) and polyethylene glycol (PEG) biomolecules. DIBA-Cy5 can serve as a fluorescent ligand, suitable for probe attachment through click chemistry. DIBA-Cy5 exerts a high binding affinity to type-2 mAChR (M2R) with the Kd value of 1.80 nM, can directly stain M2R receptors in the sinoatrial node of a mouse heart.
    DIBA-Cy5
  • HY-148526
    β2AR/M3-receptor agonist-1
    Agonist
    β2AR/M3-receptor agonist-1 (example 9) is a potent β2AR and M3 receptor agonist. β2AR/M3-receptor agonist-1 shows M3 receptor affinity with a pIC50 value of 9.3. β2AR/M3-receptor agonist-1 has the potential for the research of respiratory tract disorders.
    β2AR/M3-receptor agonist-1
  • HY-B0954A
    Oxyphencyclimine
    Antagonist
    Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm.
    Oxyphencyclimine
  • HY-B0520AS
    Benztropine-13C,d3 mesylate
    Inhibitor
    Benztropine-13C,d3 (mesylate) is the 13C- and deuterium labeled Benztropine (mesylate). Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects[1][2].
    Benztropine-<sup>13</sup>C,d<sub>3</sub> mesylate
Cat. No. Product Name / Synonyms Application Reactivity

mAChR1

mAChR2

mAChR3

mAChR4

mAChR5

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

mAChR Inhibitors, Agonists, Antagonists, Activators & Modulators
Product NamemAChR1mAChR2mAChR3mAChR4mAChR5Purity    
Clozapine N-oxide  
mAChR3
mAChR4
 99.98%
Deschloroclozapine  
mAChR3
mAChR4
 99.83%
Pilocarpine Hydrochloride  
mAChR3
  99.98%
Clozapine N-oxide dihydrochloride  
mAChR3
mAChR4
 99.74%
Pilocarpine  
mAChR3
  99.89%
p-F-HHSiD hydrochloride  
mAChR3
  
Clozapine
mAChR1, Ki: 9.5 nM (Antagonist)
  
mAChR4, EC50: 11 nM (Agonist)
 99.84%
Xanomeline
mAChR1
  
mAChR4
 99.52%
Methacholine chloride  
mAChR3
  ≥98.0%
Darifenacin hydrobromide  
mAChR3
  99.97%
(S)-(+)-Dimethindene maleate
mAChR1, pKi: 7.08
mAChR2, pKi: 7.78
mAChR3, pKi: 6.70
mAChR4, pKi: 7.00
 99.94%
Atropine sulfate   
mAChR4
 99.63%
DREADD agonist 21  
mAChR3
  99.46%
Iperoxo
mAChR1, pEC50: 9.87
mAChR2, pEC50: 10.1
mAChR3, pEC50: 9.78
  99.48%
Oxotremorine sesquifumarate 
mAChR2
   ≥98.0%
4-DAMP  
mAChR3
 
mAChR5
99.99%
Trospium chloride
mAChR1
mAChR2
mAChR3
  99.88%
Bethanechol chloride
mAChR1
 
mAChR3
mAChR4
mAChR5
98.15%
Pirenzepine dihydrochloride
mAChR1
    99.84%
Atropine sulfate monohydrate   
mAChR4
 99.68%
DREADD agonist 21 dihydrochloride  
mAChR3
  98.94%
Pilocarpine nitrate  
mAChR3
  99.83%
VU 0255035
mAChR1
    99.76%
Fesoterodine fumarate
mAChR1
 
mAChR3
mAChR4
mAChR5
99.73%
Diphenidol hydrochloride
mAChR1
mAChR2
mAChR3
mAChR4
 99.95%
VU0467154   
mAChR4
 99.56%
Tropicamide   
mAChR4
 99.22%
Ipratropium bromide
mAChR1
mAChR2
mAChR3
  99.92%
Darifenacin  
mAChR3
  99.81%
Cevimeline hydrochloride hemihydrate
mAChR1
 
mAChR3
  99.52%
(Rac)-5-Hydroxymethyl Tolterodine
mAChR1
 
mAChR3
mAChR4
mAChR5
99.59%
Cevimeline hydrochloride
mAChR1
 
mAChR3
  98.74%
N-Desmethylclozapine
mAChR1
    98.99%
Telenzepine dihydrochloride
mAChR1
    99.08%
Otenzepad 
mAChR2
   99.93%
VU0357017 hydrochloride
mAChR1
    99.91%
Dicyclomine hydrochloride
mAChR1
mAChR2
   ≥98.0%
Fesoterodine L-mandelate
mAChR1
 
mAChR3
mAChR4
mAChR5
99.00%
Aceclidine
mAChR1
 
mAChR3
  99.23%
Smilagenin
mAChR1
    ≥98.0%
VU6028418   
mAChR4
 99.52%
Imidafenacin  
mAChR3
  99.32%
Biperiden hydrochloride
mAChR1
    99.90%
VU0152100   
mAChR4
 98.98%
McN-A-343
mAChR1
    99.77%
VU 0238429    
mAChR5
99.96%
VU6019650    
mAChR5, IC50: 36 nM
98.61%
Trihexyphenidyl hydrochloride
mAChR1
    99.93%
JHU37160  
mAChR3
mAChR4
 99.98%
VU0364572 TFA
mAChR1, EC50: 0.11 μM
    99.27%
Batefenterol 
mAChR2
mAChR3
  98.30%
Penehyclidine hydrochloride
mAChR1
 
mAChR3
  99.2%
Sofpironium bromide  
mAChR3
mAChR4
mAChR5
98.26%
Solifenacin
mAChR1
mAChR2
mAChR3
  99.83%
PD 102807   
mAChR4
 98.52%
TBPB
mAChR1, EC50: 289 nM
    99.74%
Umeclidinium bromide
mAChR1
   
mAChR5
99.72%
VU 6008667    
mAChR5
99.53%
Talsaclidine 
mAChR2
mAChR3
  ≥98.0%
ML375    
mAChR5
99.70%
Clozapine (Standard)
mAChR1
  
mAChR4
 99.98%
Ipratropium bromide hydrate
mAChR1, IC50: 2.9 nM
mAChR2, IC50: 2 nM
mAChR3, IC50: 1.7 nM
  99.90%
ASP8302  
mAChR3
  98.95%
Olanzapine-d3
mAChR1
    99.09%
LY2119620 
mAChR2
 
mAChR4
 99.74%
VU 0365114    
mAChR5
99.41%
PCS1055 dihydrochloride   
mAChR4
 98.88%
VU0467485   
mAChR4
 ≥99.0%
JHU37152  
mAChR3
mAChR4
 99.45%
HY-078020  
mAChR3
  98.87%
Fesoterodine
mAChR1
 
mAChR3
mAChR4
mAChR5
99.02%
Tarafenacin D-tartrate  
mAChR3
  99.86%
(Rac)-5-Hydroxymethyl Tolterodine hydrochloride
mAChR1
 
mAChR3
mAChR4
mAChR5
AC260584
mAChR1
    99.60%
VU6004256
mAChR1, EC50: 155 nM
    99.61%
Solifenacin hydrochloride
mAChR1
mAChR2
mAChR3
  99.71%
PCS1055   
mAChR4, IC50: 18.1 nM
mAChR4, Kd: 5.72 nM
 98.02%
VU10010   
mAChR4
 98.70%
mAChR antagonist 1
mAChR1, Ki: 255 nM
mAChR2, Ki: >1000 nM
mAChR3, Ki: 121 nM
mAChR4, Ki: 158 nM
mAChR5, Ki: 255 nM
99.59%
PDE4-IN-4  
mAChR3
  
VLVNTFCDSCIPKTYWNLGY TFA  
mAChR3
  
VU0448088   
mAChR4, EC50: 56 nM
 98.67%
Bethanechol
mAChR1
 
mAChR3
mAChR4
mAChR5
Tarafenacin  
mAChR3
  
YM-58790
mAChR1, Ki: 28 nM
mAChR2, Ki: 260 nM
mAChR3, Ki: 15 nM
  98.21%
Cevimeline
mAChR1
 
mAChR3
  
(Rac)-VU 6008667    
mAChR5
99.85%
Penehyclidine
mAChR1
 
mAChR3
  
rel-Biperiden EP impurity A-d5
mAChR1
    
Solifenacin D5 hydrochloride
mAChR1
mAChR2
mAChR3
  
M1/M4 muscarinic agonist 1
mAChR1, EC50: 55 nM
  
mAChR4, EC50: 14 nM
 
N-Desmethylclozapine-d8
mAChR1
    
Pilocarpine-d3 hydrochloride  
mAChR3
  
Solifenacin-d5 succinate
mAChR1
mAChR2
mAChR3
  
YM-58790 free base
mAChR1, Ki: 28 nM
mAChR2, Ki: 260 nM
mAChR3, Ki: 15 nM
  
Pirenzepine-d8
mAChR1
    
PTAC oxalate
mAChR1, Ki: 0.6 nM
mAChR2, Ki: 2.8 nM
mAChR3, Ki: 0.2 nM
mAChR4, Ki: 0.2 nM
mAChR5, Ki: 0.8 nM
(±)-Darifenacin-d4 hydrobromide  
mAChR3
  
LAS190792
mAChR1, pIC50: 8.9
mAChR2, pIC50: 8.8
mAChR3, pIC50: 8.8
mAChR4, pIC50: 9.2
mAChR5, pIC50: 8.2
DIBA-Cy5
mAChR1, Kd: 104.5 nM
mAChR2, Kd: 1.80 nM
   
Atropine hydrobromide   
mAChR4
 
M4 mAChR Modulator-1   
mAChR4
 
Lu 26-046
mAChR1, Ki: 0.51 nM
mAChR2, Ki: 26 nM
mAChR3, Ki: 5 nM
  
5-Hydroxymethyl Tolterodine-d14 formate
mAChR1
 
mAChR3
mAChR4
mAChR5
M1 ligand 1
mAChR1
    
J 104129 fumarate 
mAChR2, Ki: 490 nM
mAChR3, Ki: 4.2 nM
  
Umeclidinium-d5 bromide
mAChR1
   
mAChR5
rel-Biperiden EP impurity B-d5
mAChR1
    
Hexocyclium methylsulfate
mAChR1, pKi: 8.9
mAChR2, pKi: 7.7
mAChR3, pKi: 8.4
mAChR4, pKi: 8.8
 
Diphenidol
mAChR1
mAChR2
mAChR3
mAChR4
 
Dicyclomine
mAChR1
mAChR2
   
Solifenacin-d7 hydrochloride
mAChR1
mAChR2
mAChR3
  
Biperiden-d5 hydrochloride
mAChR1
    
Clozapine dihydrochloride
mAChR1, Ki: 9.5 nM
  
mAChR4, EC50: 11 nM
 
(±)-Darifenacin-d4  
mAChR3
  
Umeclidinium-d10 bromide
mAChR1
   
mAChR5
MHP 133
mAChR1
mAChR2
   
Navafenterol  
mAChR3
  
M1/M2/M4 muscarinic agonist 1
mAChR1, EC50: 26 nM
mAChR2, EC50: 210 nM
 
mAChR4, EC50: 6.5 nM
 
Aceclidine hydrochloride
mAChR1
 
mAChR3
  ≥98.0%
CHF-6550  
mAChR3, pKi: 9.3
  
Darifenacin (hydrobromide) (Standard)  
mAChR3
  
TAAR1 agonist 2 
mAChR2, pEC50: 5
   
Navafenterol saccharinate  
mAChR3
  
rel-Biperiden-d5
mAChR1
    
Direclidine   
mAChR4
 
Sofpironium tosylate
mAChR1
mAChR2
mAChR3
mAChR4
mAChR5
Trihexyphenidyl-d5 hydrochloride
mAChR1
    
PF-3635659  
mAChR3
  
AE9C90CB
mAChR1, pKi: 9.7
mAChR2, pKi: 8.6
mAChR3, pKi: 9.9
mAChR4, pKi: 9.5
mAChR5, pKi: 9.5
Alvameline  
mAChR3
  
Revatropate
mAChR1
mAChR2
mAChR3
  
Atropine oxide hydrochloride
mAChR1
mAChR2
mAChR3
mAChR4
mAChR5
Rispenzepine
mAChR1
 
mAChR3
  
(1R,3S-)Solifenacin-d5 hydrochloride
mAChR1
mAChR2
mAChR3
  
Clozapine hydrochloride
mAChR1, Ki: 9.5 nM
  
mAChR4, EC50: 11 nM